Compugen announces $15M funding agreement for Korean subsidiary Compugen announced the signing of an agreement with a private U.S.-based investment company pursuant to which up to $15M in milestone related equity financing will be made available to Keddem Bioscience Ltd., currently a wholly owned subsidiary of Compugen. This financing will be used to further develop and commercialize a unique technology platform that has been designed to consistently enable the discovery of small molecule modulators for potentially any given protein target. Under the agreement, the new investor will obtain a majority equity interest in Keddem, with Compugen maintaining a minority interest and certain future preferential access rights to utilize the Keddem technology with Compugen discovered drug targets.
News For CGEN From The Last 14 Days
Check below for free stories on CGEN the last two weeks.